Unlock the thermogenic potential of adipose tissue: Pharmacological modulation and implications for treatment of diabetes and obesity

Frontiers in Endocrinology

Volumn 6, Issue NOV, 2015, Pages

  Peng, Xiao Rong ^a   Gennemark, Peter ^a   O'Mahony, Gavin ^a   Bartesaghi, Stefano ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Brown adipose tissue; Drug discovery; FGF21 analogs; PPAR agonists; Thermogenesis; Thiazolidinediones; Uncoupling protein 1; 3 adrenergic receptor agonists

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BETA 3 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; EPHEDRINE; FIBROBLAST GROWTH FACTOR 21; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE;

BASAL METABOLIC RATE; BODY MASS; BROWN ADIPOCYTE; BROWN ADIPOSE TISSUE; DIABETES MELLITUS; GLUCOSE TRANSPORT; HUMAN; INSULIN SENSITIVITY; METABOLISM; NONHUMAN; OBESITY; REVIEW; THERMOGENESIS; WEIGHT REDUCTION;

EID: 84949814146     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2015.00174     Document Type: Review

References (145)

1. IDF DIABETES ATLAS Sixth edition (2013). Available from: https://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf
2. Cypess AM, Lehman S, Williams G, Tal I, Rodman D, Goldfine AB, et al. Identification and importance of brown adipose tissue in adult humans. N Engl J Med (2009) 360:1509-17. doi: 10.1056/NEJMoa0810780
3. Nedergaard J, Bengtsson T, Cannon B. Unexpected evidence for active brown adipose tissue in adult humans. Am J Physiol Endocrinol Metab (2007) 293:E444-52. doi:10.1152/ajpendo.00691.2006
4. van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, Drossaerts JM, Kemerink GJ, Bouvy ND, et al. Cold-activated brown adipose tissue in healthy men. N Engl J Med (2009) 360:1500-8. doi:10.1056/NEJMoa0808718
5. Virtanen KA, Lidell ME, Orava J, Heglind M, Westergren R, Niemi T, et al. Functional brown adipose tissue in healthy adults. N Engl J Med (2009) 360:1518-25. doi:10.1056/NEJMoa0808949
6. Betz MJ, Enerback S. Human brown adipose tissue: what we have learned so far. Diabetes (2015) 64:2352-60. doi:10.2337/db15-0146
7. Blondin DP, Labbe SM, Phoenix S, Guerin B, Turcotte EE, Richard D, et al. Contributions of white and brown adipose tissues and skeletal muscles to acute cold-induced metabolic responses in healthy men. J Physiol (2015) 593:701-14. doi:10.1113/jphysiol.2014.283598
8. Chechi K, Carpentier AC, Richard D. Understanding the brown adipocyte as a contributor to energy homeostasis. Trends Endocrinol Metab (2013) 24:408-20. doi:10.1016/j.tem.2013.04.002
9. Harms M, Seale P. Brown and beige fat: development, function and therapeutic potential. Nat Med (2013) 19:1252-63. doi:10.1038/nm.3361
10. Nedergaard J, Cannon B. The browning of white adipose tissue: some burning issues. Cell Metab (2014) 20:396-407. doi:10.1016/j.cmet.2014.07.005
11. van Marken Lichtenbelt WD, Schrauwen P. Implications of nonshivering thermogenesis for energy balance regulation in humans. Am J Physiol Regul Integr Comp Physiol (2011) 301:R285-96. doi:10.1152/ajpregu.00652.2010
12. Vosselman MJ, van Marken Lichtenbelt WD, Schrauwen P. Energy dissipation in brown adipose tissue: from mice to men. Mol Cell Endocrinol (2013) 379:43-50. doi:10.1016/j.mce.2013.04.017
13. Cannon B, Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol Rev (2004) 84:277-359. doi:10.1152/physrev.00015.2003
14. Enerback S. Human brown adipose tissue. Cell Metab (2010) 11:248-52. doi:10.1016/j.cmet.2010.03.008
15. Lidell ME, Betz MJ, Dahlqvist Leinhard O, Heglind M, Elander L, Slawik M, et al. Evidence for two types of brown adipose tissue in humans. Nat Med (2013) 19:631-4. doi:10.1038/nm.3017
16. Frontini A, Vitali A, Perugini J, Murano I, Romiti C, Ricquier D, et al. White-to-brown transdifferentiation of omental adipocytes in patients affected by pheochromocytoma. Biochim Biophys Acta (2013) 1831:950-9. doi:10.1016/j.bbalip.2013.02.005
17. Ricquier D, Nechad M, Mory G. Ultrastructural and biochemical characterization of human brown adipose tissue in pheochromocytoma. J Clin Endocrinol Metab (1982) 54:803-7.
18. Sidossis LS, Porter C, Saraf MK, Borsheim E, Radhakrishnan RS, Chao T, et al. Browning of subcutaneous white adipose tissue in humans after severe adrenergic stress. Cell Metab (2015) 22:219-27. doi:10.1016/j.cmet.2015.06.022
19. Seale P, Bjork B, Yang W, Kajimura S, Chin S, Kuang S, et al. PRDM16 controls a brown fat/skeletal muscle switch. Nature (2008) 454:961-7. doi:10.1038/nature07182
20. Timmons JA, Wennmalm K, Larsson O, Walden TB, Lassmann T, Petrovic N, et al. Myogenic gene expression signature establishes that brown and white adipocytes originate from distinct cell lineages. Proc Natl Acad Sci U S A (2007) 104:4401-6. doi:10.1073/pnas.0610615104
21. Wang Q, Zhang M, Xu M, Gu W, Xi Y, Qi L, et al. Brown adipose tissue activation is inversely related to central obesity and metabolic parameters in adult human. PLoS One (2015) 10:e0123795. doi:10.1371/journal.pone.0123795
22. Saito M, Okamatsu-Ogura Y, Matsushita M, Watanabe K, Yoneshiro T, Nio-Kobayashi J, et al. High incidence of metabolically active brown adipose tissue in healthy adult humans: effects of cold exposure and adiposity. Diabetes (2009) 58:1526-31. doi:10.2337/db09-0530
23. Persichetti A, Sciuto R, Rea S, Basciani S, Lubrano C, Mariani S, et al. Prevalence, mass, and glucose-uptake activity of (1)(8)F-FDG-detected brown adipose tissue in humans living in a temperate zone of Italy. PLoS One (2013) 8:e63391. doi:10.1371/journal.pone.0063391
24. Lee P, Greenfield JR, Ho KK, Fulham MJ. A critical appraisal of the prevalence and metabolic significance of brown adipose tissue in adult humans. Am J Physiol Endocrinol Metab (2010) 299:E601-6. doi:10.1152/ajpendo.00298.2010
25. Lee P, Swarbrick MM, Zhao JT, Ho KK. Inducible brown adipogenesis of supraclavicular fat in adult humans. Endocrinology (2011) 152:3597-602. doi:10.1210/en.2011-1349
26. Ouellet V, Labbe SM, Blondin DP, Phoenix S, Guerin B, Haman F, et al. Brown adipose tissue oxidative metabolism contributes to energy expenditure during acute cold exposure in humans. J Clin Invest (2012) 122:545-52. doi:10.1172/JCI60433
27. Vijgen GH, Bouvy ND, Teule GJ, Brans B, Hoeks J, Schrauwen P, et al. Increase in brown adipose tissue activity after weight loss in morbidly obese subjects. J Clin Endocrinol Metab (2012) 97:E1229-33. doi:10.1210/jc.2012-1289
28. Cypess AM, White AP, Vernochet C, Schulz TJ, Xue R, Sass CA, et al. Anatomical localization, gene expression profiling and functional characterization of adult human neck brown fat. Nat Med (2013) 19:635-9. doi:10.1038/nm.3112
29. Jespersen NZ, Larsen TJ, Peijs L, Daugaard S, Homoe P, Loft A, et al. A classical brown adipose tissue mRNA signature partly overlaps with brite in the supraclavicular region of adult humans. Cell Metab (2013) 17:798-805. doi:10.1016/j.cmet.2013.04.011
30. Sharp LZ, Shinoda K, Ohno H, Scheel DW, Tomoda E, Ruiz L, et al. Human BAT possesses molecular signatures that resemble beige/brite cells. PLoS One (2012) 7:e49452. doi:10.1371/journal.pone.0049452
31. Wu J, Bostrom P, Sparks LM, Ye L, Choi JH, Giang AH, et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell (2012) 150:366-76. doi:10.1016/j.cell.2012.05.016
32. Bartelt A, Bruns OT, Reimer R, Hohenberg H, Ittrich H, Peldschus K, et al. Brown adipose tissue activity controls triglyceride clearance. Nat Med (2011) 17:200-5. doi:10.1038/nm.2297
33. Labbe SM, Caron A, Bakan I, Laplante M, Carpentier AC, Lecomte R, et al. In vivo measurement of energy substrate contribution to cold-induced brown adipose tissue thermogenesis. FASEB J (2015) 29:2046-58. doi:10.1096/fj.14-266247
34. Bartelt A, Heeren J. Adipose tissue browning and metabolic health. Nat Rev Endocrinol (2014) 10:24-36. doi:10.1038/nrendo.2013.204
35. Seale P, Conroe HM, Estall J, Kajimura S, Frontini A, Ishibashi J, et al. Prdm16 determines the thermogenic program of subcutaneous white adipose tissue in mice. J Clin Invest (2011) 121:96-105. doi:10.1172/JCI44271
36. Abreu-Vieira G, Xiao C, Gavrilova O, Reitman ML. Integration of body temperature into the analysis of energy expenditure in the mouse. Mol Metab (2015) 4:461-70. doi:10.1016/j.molmet.2015.03.001
37. Rothwell NJ, Stock MJ. Whither brown fat? Biosci Rep (1986) 6:3-18. doi:10.1007/BF01145174
38. Hall KD, Sacks G, Chandramohan D, Chow CC, Wang YC, Gortmaker SL, et al. Quantification of the effect of energy imbalance on bodyweight. Lancet (2011) 378:826-37. doi:10.1016/S0140-6736(11)60812-X
39. Gennemark P, Hjorth S, Gabrielsson J. Modeling energy intake by adding homeostatic feedback and drug intervention. J Pharmacokinet Pharmacodyn (2015) 42:79-96. doi:10.1007/s10928-014-9399-4
40. Cannon B, Nedergaard J. Thermogenesis challenges the adipostat hypothesis for body-weight control. Proc Nutr Soc (2009) 68:401-7. doi:10.1017/S0029665109990255
41. Cypess AM, Weiner LS, Roberts-Toler C, Franquet Elia E, Kessler SH, Kahn PA, et al. Activation of human brown adipose tissue by a beta3-adrenergic receptor agonist. Cell Metab (2015) 21:33-8. doi:10.1016/j.cmet.2014.12.009
42. McAdam-Marx C, Mukherjee J, Bellows BK, Unni S, Ye X, Iloeje U, et al. Evaluation of the relationship between weight change and glycemic control after initiation of antidiabetic therapy in patients with type 2 diabetes using electronic medical record data. Diabetes Res Clin Pract (2014) 103:402-11. doi:10.1016/j.diabres.2013.12.038
43. Hanssen MJ, Hoeks J, Brans B, van der Lans AA, Schaart G, van den Driessche JJ, et al. Short-term cold acclimation improves insulin sensitivity in patients with type 2 diabetes mellitus. Nat Med (2015) 21:863-5. doi:10.1038/nm.3891
44. Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest (2014) 124:509-14. doi:10.1172/JCI70704
45. Bartesaghi S, Hallen S, Huang L, Svensson PA, Momo RA, Wallin S, et al. Thermogenic activity of UCP1 in human white fat-derived beige adipocytes. Mol Endocrinol (2015) 29:130-9. doi:10.1210/me.2014-1295
46. Shabalina IG, Petrovic N, de Jong JM, Kalinovich AV, Cannon B, Nedergaard J. UCP1 in brite/beige adipose tissue mitochondria is functionally thermogenic. Cell Rep (2013) 5:1196-203. doi:10.1016/j.celrep.2013.10.044
47. Seale P. Transcriptional regulatory circuits controlling brown fat development and activation. Diabetes (2015) 64:2369-75. doi:10.2337/db15-0203
48. Wu J, Jun H, McDermott JR. Formation and activation of thermogenic fat. Trends Genet (2015) 31:232-8. doi:10.1016/j.tig.2015.03.003
49. Festuccia WT, Blanchard PG, Deshaies Y. Control of brown adipose tissue glucose and lipid metabolism by PPARgamma. Front Endocrinol (2011) 2:84. doi:10.3389/fendo.2011.00084
50. Arch JR. The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from beta3-adrenoceptor agonists. Naunyn Schmiedebergs Arch Pharmacol (2008) 378:225-40. doi:10.1007/s00210-008-0271-1
51. Atgie C, D'Allaire F, Bukowiecki LJ. Role of beta1-and beta3-adrenoceptors in the regulation of lipolysis and thermogenesis in rat brown adipocytes. Am J Physiol (1997) 273:C1136-42.
52. Granneman JG. Why do adipocytes make the beta 3 adrenergic receptor? Cell Signal (1995) 7:9-15. doi:10.1016/0898-6568(94)00066-K
53. Lowell BB, Flier JS. Brown adipose tissue, beta 3-adrenergic receptors, and obesity. Annu Rev Med (1997) 48:307-16. doi:10.1146/annurev.med.48.1.307
54. Muzzin P, Revelli JP, Kuhne F, Gocayne JD, McCombie WR, Venter JC, et al. An adipose tissue-specific beta-adrenergic receptor. Molecular cloning and down-regulation in obesity. J Biol Chem (1991) 266:24053-8.
55. Carey AL, Formosa MF, Van Every B, Bertovic D, Eikelis N, Lambert GW, et al. Ephedrine activates brown adipose tissue in lean but not obese humans. Diabetologia (2013) 56:147-55. doi:10.1007/s00125-012-2748-1
56. Cypess AM, Chen YC, Sze C, Wang K, English J, Chan O, et al. Cold but not sympathomimetics activates human brown adipose tissue in vivo. Proc Natl Acad Sci U S A (2012) 109:10001-5. doi:10.1073/pnas.1207911109
57. Vosselman MJ, van der Lans AA, Brans B, Wierts R, van Baak MA, Schrauwen P, et al. Systemic beta-adrenergic stimulation of thermogenesis is not accompanied by brown adipose tissue activity in humans. Diabetes (2012) 61:3106-13. doi:10.2337/db12-0288
58. Nicholls DG. A history of UCP1. Biochem Soc Trans (2001) 29:751-5. doi:10.1042/bst0290751
59. Ahmadian M, Abbott MJ, Tang T, Hudak CS, Kim Y, Bruss M, et al. Desnutrin/ATGL is regulated by AMPK and is required for a brown adipose phenotype. Cell Metab (2011) 13:739-48. doi:10.1016/j.cmet.2011.05.002
60. Li Y, Fromme T, Schweizer S, Schottl T, Klingenspor M. Taking control over intracellular fatty acid levels is essential for the analysis of thermogenic function in cultured primary brown and brite/beige adipocytes. EMBO Rep (2014) 15:1069-76. doi:10.15252/embr.201438775
61. Mottillo EP, Bloch AE, Leff T, Granneman JG. Lipolytic products activate peroxisome proliferator-activated receptor (PPAR) alpha and delta in brown adipocytes to match fatty acid oxidation with supply. J Biol Chem (2012) 287:25038-48. doi:10.1074/jbc.M112.374041
62. Zechner R. FLUX FAT: enzymes, regulators, and pathophysiology of intracellular lipolysis. EMBO Mol Med (2015) 7:359-62. doi:10.15252/emmm.201404846
63. Kajimura S, Saito M. A new era in brown adipose tissue biology: molecular control of brown fat development and energy homeostasis. Annu Rev Physiol (2014) 76:225-49. doi:10.1146/annurev-physiol-021113-170252
64. Collins S, Daniel KW, Rohlfs EM, Ramkumar V, Taylor IL, Gettys TW. Impaired expression and functional activity of the beta 3-and beta 1-adrenergic receptors in adipose tissue of congenitally obese (C57BL/6J ob/ob) mice. Mol Endocrinol (1994) 8:518-27. doi:10.1210/me.8.4.518
65. Triandafillou J, Himms-Hagen J. Brown adipose tissue in genetically obese (fa/fa) rats: response to cold and diet. Am J Physiol (1983) 244:E145-50.
66. Rogers NH, Landa A, Park S, Smith RG. Aging leads to a programmed loss of brown adipocytes in murine subcutaneous white adipose tissue. Aging Cell (2012) 11:1074-83. doi:10.1111/acel.12010
67. Rafael J, Fesser W, Nicholls DG. Cold adaptation in guinea pig at level of isolated brown adipocyte. Am J Physiol (1986) 250:C228-35.
68. Blondin DP, Labbe SM, Noll C, Kunach M, Phoenix S, Guerin B, et al. Selective impairment of glucose but not fatty acid or oxidative metabolism in brown adipose tissue of subjects with type 2 diabetes. Diabetes (2015) 64:2388-97. doi:10.2337/db14-1651
69. Blondin DP, Labbe SM, Tingelstad HC, Noll C, Kunach M, Phoenix S, et al. Increased brown adipose tissue oxidative capacity in cold-acclimated humans. J Clin Endocrinol Metab (2014) 99:E438-46. doi:10.1210/jc.2013-3901
70. Lee P, Smith S, Linderman J, Courville AB, Brychta RJ, Dieckmann W, et al. Temperature-acclimated brown adipose tissue modulates insulin sensitivity in humans. Diabetes (2014) 63:3686-98. doi:10.2337/db14-0513
71. Rosenwald M, Perdikari A, Rulicke T, Wolfrum C. Bi-directional interconversion of brite and white adipocytes. Nat Cell Biol (2013) 15:659-67. doi:10.1038/ncb2740
72. Soccio RE, Chen ER, Lazar MA. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab (2014) 20:573-91. doi:10.1016/j.cmet.2014.08.005
73. Oakes ND, Thalen PG, Jacinto SM, Ljung B. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Diabetes (2001) 50:1158-65. doi:10.2337/diabetes.50.5.1158
74. Digby JE, Montague CT, Sewter CP, Sanders L, Wilkison WO, O'Rahilly S, et al. Thiazolidinedione exposure increases the expression of uncoupling protein 1 in cultured human preadipocytes. Diabetes (1998) 47:138-41. doi:10.2337/diab.47.1.138
75. Elabd C, Chiellini C, Carmona M, Galitzky J, Cochet O, Petersen R, et al. Human multipotent adipose-derived stem cells differentiate into functional brown adipocytes. Stem Cells (2009) 27:2753-60. doi:10.1002/stem.200
76. Ohno H, Shinoda K, Spiegelman BM, Kajimura S. PPARgamma agonists induce a white-to-brown fat conversion through stabilization of PRDM16 protein. Cell Metab (2012) 15:395-404. doi:10.1016/j.cmet.2012.01.019
77. Petrovic N, Shabalina IG, Timmons JA, Cannon B, Nedergaard J. Thermogenically competent nonadrenergic recruitment in brown preadipocytes by a PPARgamma agonist. Am J Physiol Endocrinol Metab (2008) 295:E287-96. doi:10.1152/ajpendo.00035.2008
78. Sears DD, Hsiao G, Hsiao A, Yu JG, Courtney CH, Ofrecio JM, et al. Mechanisms of human insulin resistance and thiazolidinedione-mediated insulin sensitization. Proc Natl Acad Sci U S A (2009) 106:18745-50. doi:10.1073/pnas.0903032106
79. Burkey BF, Dong M, Gagen K, Eckhardt M, Dragonas N, Chen W, et al. Effects of pioglitazone on promoting energy storage, not expenditure, in brown adipose tissue of obese fa/fa Zucker rats: comparison to CL 316,243. Metabolism (2000) 49:1301-8. doi:10.1053/meta.2000.9524
80. Kelly LJ, Vicario PP, Thompson GM, Candelore MR, Doebber TW, Ventre J, et al. Peroxisome proliferator-activated receptors gamma and alpha mediate in vivo regulation of uncoupling protein (UCP-1, UCP-2, UCP-3) gene expression. Endocrinology (1998) 139:4920-7. doi:10.1210/en.139.12.4920
81. Smith SR, De Jonge L, Volaufova J, Li Y, Xie H, Bray GA. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism (2005) 54:24-32. doi:10.1016/j.metabol.2004.07.008
82. Sell H, Berger JP, Samson P, Castriota G, Lalonde J, Deshaies Y, et al. Peroxisome proliferator-activated receptor gamma agonism increases the capacity for sympathetically mediated thermogenesis in lean and ob/ob mice. Endocrinology (2004) 145:3925-34. doi:10.1210/en.2004-0321
83. Festuccia WT, Blanchard PG, Oliveira TB, Magdalon J, Paschoal VA, Richard D, et al. PPARgamma activation attenuates cold-induced upregulation of thyroid status and brown adipose tissue PGC-1alpha and D2. Am J Physiol Regul Integr Comp Physiol (2012) 303:R1277-85. doi:10.1152/ajpregu.00299.2012
84. Festuccia WT, Blanchard PG, Turcotte V, Laplante M, Sariahmetoglu M, Brindley DN, et al. The PPARgamma agonist rosiglitazone enhances rat brown adipose tissue lipogenesis from glucose without altering glucose uptake. Am J Physiol Regul Integr Comp Physiol (2009) 296:R1327-35. doi:10.1152/ajpregu.91012.2008
85. Bakopanos E, Silva JE. Thiazolidinediones inhibit the expression of beta3-adrenergic receptors at a transcriptional level. Diabetes (2000) 49:2108-15. doi:10.2337/diabetes.49.12.2108
86. Festuccia WT, Oztezcan S, Laplante M, Berthiaume M, Michel C, Dohgu S, et al. Peroxisome proliferator-activated receptor-gamma-mediated positive energy balance in the rat is associated with reduced sympathetic drive to adipose tissues and thyroid status. Endocrinology (2008) 149:2121-30. doi:10.1210/en.2007-1553
87. Bogacka I, Ukropcova B, McNeil M, Gimble JM, Smith SR. Structural and functional consequences of mitochondrial biogenesis in human adipocytes in vitro. J Clin Endocrinol Metab (2005) 90:6650-6. doi:10.1210/jc.2005-1024
88. Bogacka I, Gettys TW, de Jonge L, Nguyen T, Smith JM, Xie H, et al. The effect of beta-adrenergic and peroxisome proliferator-activated receptor-gamma stimulation on target genes related to lipid metabolism in human subcutaneous adipose tissue. Diabetes Care (2007) 30:1179-86. doi:10.2337/dc06-1962
89. Nettles KW, Greene GL. Ligand control of coregulator recruitment to nuclear receptors. Annu Rev Physiol (2005) 67:309-33. doi:10.1146/annurev.physiol.66.032802.154710
90. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem (1995) 270:12953-6. doi:10.1074/jbc.270.22.12953
91. Cho N, Momose Y. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress. Curr Top Med Chem (2008) 8:1483-507. doi:10.2174/156802608786413474
92. Henke BR. 1. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands and their therapeutic utility. Prog Med Chem (2004) 42:1-53. doi:10.1016/S0079-6468(04)42001-3
93. Nevin DK, Lloyd DG, Fayne D. Rational targeting of peroxisome proliferating activated receptor subtypes. Curr Med Chem (2011) 18:5598-623. doi:10.2174/092986711798347243
94. Savkur RS, Miller AR. Investigational PPAR-gamma agonists for the treatment of Type 2 diabetes. Expert Opin Investig Drugs (2006) 15:763-78. doi:10.1517/13543784.15.7.763
95. Takada I, Makishima M. PPARgamma ligands and their therapeutic applications: a patent review (2008-2014). Expert Opin Ther Pat (2015) 25:175-91. doi:10.1517/13543776.2014.985206
96. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem (2000) 43:527-50. doi:10.1021/jm990554g
97. Garcia-Vallve S, Guasch L, Tomas-Hernandez S, Del Bas JM, Ollendorff V, Arola L, et al. Peroxisome proliferator-activated receptor gamma (PPARgamma) and ligand choreography: newcomers take the stage. J Med Chem (2015) 58:5381-94. doi:10.1021/jm501155f
98. Abbas A, Blandon J, Rude J, Elfar A, Mukherjee D. PPAR-gamma agonist in treatment of diabetes: cardiovascular safety considerations. Cardiovasc Hematol Agents Med Chem (2012) 10:124-34. doi:10.2174/187152512800388948
99. Bortolini M, Wright MB, Bopst M, Balas B. Examining the safety of PPAR agonists - current trends and future prospects. Expert Opin Drug Saf (2013) 12:65-79. doi:10.1517/14740338.2013.741585
100. Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B. Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta (2007) 1771:1065-81. doi:10.1016/j.bbalip.2007.02.003
101. Tang WH, Maroo A. PPARgamma agonists: safety issues in heart failure. Diabetes Obes Metab (2007) 9:447-54. doi:10.1111/j.1463-1326.2006.00616.x
102. Germain P, Iyer J, Zechel C, Gronemeyer H. Co-regulator recruitment and the mechanism of retinoic acid receptor synergy. Nature (2002) 415:187-92. doi:10.1038/415187a
103. Hamza MS, Pott S, Vega VB, Thomsen JS, Kandhadayar GS, Ng PW, et al. De-novo identification of PPARgamma/RXR binding sites and direct targets during adipogenesis. PLoS One (2009) 4:e4907. doi:10.1371/journal.pone.0004907
104. Bulynko YA, O'Malley BW. Nuclear receptor coactivators: structural and functional biochemistry. Biochemistry (2011) 50:313-28. doi:10.1021/bi101762x
105. Lonard DM, O'Malley BW. Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. Mol Cell (2007) 27:691-700. doi:10.1016/j.molcel.2007.08.012
106. Millard CJ, Watson PJ, Fairall L, Schwabe JW. An evolving understanding of nuclear receptor coregulator proteins. J Mol Endocrinol (2013) 51:T23-36. doi:10.1530/JME-13-0227
107. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature (1998) 395:137-43. doi:10.1038/25931
108. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, et al. PPARgamma signaling and metabolism: the good, the bad and the future. Nat Med (2013) 19:557-66. doi:10.1038/nm.3159
109. Banks AS, McAllister FE, Camporez JP, Zushin PJ, Jurczak MJ, Laznik-Bogoslavski D, et al. An ERK/Cdk5 axis controls the diabetogenic actions of PPARgamma. Nature (2015) 517:391-5. doi:10.1038/nature13887
110. Moisan A, Lee YK, Zhang JD, Hudak CS, Meyer CA, Prummer M, et al. White-to-brown metabolic conversion of human adipocytes by JAK inhibition. Nat Cell Biol (2015) 17:57-67. doi:10.1038/ncb3075
111. Dolan JA, Muenkel HA, Burns MG, Pellegrino SM, Fraser CM, Pietri F, et al. Beta-3 adrenoceptor selectivity of the dioxolane dicarboxylate phenethanolamines. J Pharmacol Exp Ther (1994) 269:1000-6.
112. Emorine LJ, Marullo S, Briend-Sutren MM, Patey G, Tate K, Delavier-Klutchko C, et al. Molecular characterization of the human beta 3-adrenergic receptor. Science (1989) 245:1118-21. doi:10.1126/science.2570461
113. Lelias JM, Kaghad M, Rodriguez M, Chalon P, Bonnin J, Dupre I, et al. Molecular cloning of a human beta 3-adrenergic receptor cDNA. FEBS Lett (1993) 324:127-30. doi:10.1016/0014-5793(93)81377-C
114. Hu B, Ellingboe J, Han S, Largis E, Lim K, Malamas M, et al. Novel (4-piperidin-1-yl)-phenyl sulfonamides as potent and selective human beta(3) agonists. Bioorg Med Chem (2001) 9:2045-59. doi:10.1016/S0968-0896(01)00114-6
115. Buemann B, Toubro S, Astrup A. Effects of the two beta3-agonists, ZD7114 and ZD2079 on 24 hour energy expenditure and respiratory quotient in obese subjects. Int J Obes Relat Metab Disord (2000) 24:1553-60. doi:10.1038/sj.ijo.0801452
116. Pietri-Rouxel F, Strosberg AD. Pharmacological characteristics and species-related variations of beta 3-adrenergic receptors. Fundam Clin Pharmacol (1995) 9:211-8. doi:10.1111/j.1472-8206.1995.tb00288.x
117. Mathvink RJ, Tolman JS, Chitty D, Candelore MR, Cascieri MA, Colwell LF Jr, et al. Discovery of a potent, orally bioavailable beta(3) adrenergic receptor agonist, (R)-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4-[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide. J Med Chem (2000) 43:3832-6. doi:10.1021/jm000286i
118. Harada H, Hirokawa Y, Suzuki K, Hiyama Y, Oue M, Kawashima H, et al. Discovery of a novel and potent human and rat beta3-adrenergic receptor agonist, [3-[(2R)-[[(2R)-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1H-indol-7-yloxy]acetic acid. Chem Pharm Bull (2005) 53:184-98. doi:10.1248/cpb.53.184
119. Takasu T, Ukai M, Sato S, Matsui T, Nagase I, Maruyama T, et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4'-(2-[(2-hydroxy-2-phenylethyl)amino]ethyl) acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther (2007) 321:642-7. doi:10.1124/jpet.106.115840
120. Blin N, Nahmias C, Drumare MF, Strosberg AD. Mediation of most atypical effects by species homologues of the beta 3-adrenoceptor. Br J Pharmacol (1994) 112:911-9. doi:10.1111/j.1476-5381.1994.tb13167.x
121. Larsen TM, Toubro S, van Baak MA, Gottesdiener KM, Larson P, Saris WH, et al. Effect of a 28-d treatment with L-796568, a novel beta(3)-adrenergic receptor agonist, on energy expenditure and body composition in obese men. Am J Clin Nutr (2002) 76:780-8.
122. Redman LM, de Jonge L, Fang X, Gamlin B, Recker D, Greenway FL, et al. Lack of an effect of a novel beta3-adrenoceptor agonist, TAK-677, on energy metabolism in obese individuals: a double-blind, placebo-controlled randomized study. J Clin Endocrinol Metab (2007) 92:527-31. doi:10.1210/jc.2006-1740
123. Champigny O, Ricquier D, Blondel O, Mayers RM, Briscoe MG, Holloway BR. Beta 3-adrenergic receptor stimulation restores message and expression of brown-fat mitochondrial uncoupling protein in adult dogs. Proc Natl Acad Sci U S A (1991) 88:10774-7. doi:10.1073/pnas.88.23.10774
124. Weyer C, Tataranni PA, Snitker S, Danforth E Jr, Ravussin E. Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans. Diabetes (1998) 47:1555-61. doi:10.2337/diabetes.47.10.1555
125. van Baak MA, Hul GB, Toubro S, Astrup A, Gottesdiener KM, DeSmet M, et al. Acute effect of L-796568, a novel beta 3-adrenergic receptor agonist, on energy expenditure in obese men. Clin Pharmacol Ther (2002) 71:272-9. doi:10.1067/mcp.2002.122527
126. Laeger T, Henagan TM, Albarado DC, Redman LM, Bray GA, Noland RC, et al. FGF21 is an endocrine signal of protein restriction. J Clin Invest (2014) 124:3913-22. doi:10.1172/JCI74915
127. Adams AC, Cheng CC, Coskun T, Kharitonenkov A. FGF21 requires betaklotho to act in vivo. PLoS One (2012) 7:e49977. doi:10.1371/journal.pone.0049977
128. Ding X, Boney-Montoya J, Owen BM, Bookout AL, Coate KC, Mangelsdorf DJ, et al. betaKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab (2012) 16:387-93. doi:10.1016/j.cmet.2012.08.002
129. Angelin B, Larsson TE, Rudling M. Circulating fibroblast growth factors as metabolic regulators - a critical appraisal. Cell Metab (2012) 16:693-705. doi:10.1016/j.cmet.2012.11.001
130. Gimeno RE, Moller DE. FGF21-based pharmacotherapy - potential utility for metabolic disorders. Trends Endocrinol Metab (2014) 25:303-11. doi:10.1016/j.tem.2014.03.001
131. Owen BM, Ding X, Morgan DA, Coate KC, Bookout AL, Rahmouni K, et al. FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab (2014) 20:670-7. doi:10.1016/j.cmet.2014.07.012
132. Chartoumpekis DV, Habeos IG, Ziros PG, Psyrogiannis AI, Kyriazopoulou VE, Papavassiliou AG. Brown adipose tissue responds to cold and adrenergic stimulation by induction of FGF21. Mol Med (2011) 17:736-40. doi:10.2119/molmed.2011.00075
133. Hanssen MJ, Broeders E, Samms RJ, Vosselman MJ, van der Lans AA, Cheng CC, et al. Serum FGF21 levels are associated with brown adipose tissue activity in humans. Sci Rep (2015) 5:10275. doi:10.1038/srep10275
134. Fisher FM, Kleiner S, Douris N, Fox EC, Mepani RJ, Verdeguer F, et al. FGF21 regulates PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis. Genes Dev (2012) 26:271-81. doi:10.1101/gad.177857.111
135. Lee P, Linderman JD, Smith S, Brychta RJ, Wang J, Idelson C, et al. Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans. Cell Metab (2014) 19:302-9. doi:10.1016/j.cmet.2013.12.017
136. Hondares E, Gallego-Escuredo JM, Flachs P, Frontini A, Cereijo R, Goday A, et al. Fibroblast growth factor-21 is expressed in neonatal and pheochromocytoma-induced adult human brown adipose tissue. Metabolism (2014) 63:312-7. doi:10.1016/j.metabol.2013.11.014
137. Camporez JP, Jornayvaz FR, Petersen MC, Pesta D, Guigni BA, Serr J, et al. Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice. Endocrinology (2013) 154:3099-109. doi:10.1210/en.2013-1191
138. Emanuelli B, Vienberg SG, Smyth G, Cheng C, Stanford KI, Arumugam M, et al. Interplay between FGF21 and insulin action in the liver regulates metabolism. J Clin Invest (2015) 125:458. doi:10.1172/JCI80223
139. Samms RJ, Smith DP, Cheng CC, Antonellis PP, Perfield JW II, Kharitonenkov A, et al. Discrete aspects of FGF21 in vivo pharmacology do not require UCP1. Cell Rep (2015) 11:991-9. doi:10.1016/j.celrep.2015.04.046
140. Veniant MM, Sivits G, Helmering J, Komorowski R, Lee J, Fan W, et al. Pharmacologic effects of FGF21 are independent of the "browning" of white adipose tissue. Cell Metab (2015) 21:731-8. doi:10.1016/j.cmet.2015.04.019
141. Keipert S, Kutschke M, Lamp D, Brachthauser L, Neff F, Meyer CW, et al. Genetic disruption of uncoupling protein 1 in mice renders brown adipose tissue a significant source of FGF21 secretion. Mol Metab (2015) 4:537-42. doi:10.1016/j.molmet.2015.04.006
142. Ukropec J, Anunciado RP, Ravussin Y, Hulver MW, Kozak LP. UCP1-independent thermogenesis in white adipose tissue of cold-acclimated Ucp1-/-mice. J Biol Chem (2006) 281:31894-908. doi:10.1074/jbc.M606114200
143. Dong JQ, Rossulek M, Somayaji VR, Baltrukonis D, Liang Y, Hudson K, et al. Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study. Br J Clin Pharmacol (2015) 80(5):1051-63. doi:10.1111/bcp.12676
144. Gaich G, Chien JY, Fu H, Glass LC, Deeg MA, Holland WL, et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab (2013) 18:333-40. doi:10.1016/j.cmet.2013.08.005
145. Kolumam G, Chen MZ, Tong R, Zavala-Solorio J, Kates L, van Bruggen N, et al. Sustained brown fat stimulation and insulin sensitization by a humanized bispecific antibody agonist for fibroblast growth factor receptor 1/betaKlotho complex. EBioMedicine (2015) 2:730-43. doi:10.1016/j.ebiom.2015.05.028